DDRE-12. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)

OBJECTIVE: To estimate the 6-month Progression Free Survival (PFS6) associated with everolimus for progressive/recurrent pLGGs and to determine if activated PI3K/Akt/mTOR pathway as measured by positive phosphorylated-ribosomal protein S6 (p-RPS6) status was associated with response. METHOD: Patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Mueller, Sabine, Aboian, Mariam, Nazemi, Kellie, Gauvain, Karen, Yoon, Janet, Minturn, Jane, Leary, Sarah, AbdelBaki, Mohamed, Goldman, Stewart, Elster, Jennifer, Resnick, Adam, Molinaro, Annette, Phillips, Joanna, Prados, Michael, Haas-Kogan, Daphne
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2020
Schlagworte:
Drug Discovery, Drug Resistance
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651691/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.257
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge